Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.78 |
| ▸ | MAOA | P21397 | 6/20 | 0.61 |
| ▸ | KDM1A | O60341 | 15/20 | 0.60 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159366 | 1.00 | MAOB (0.78) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17159209 | 1.00 | MAOB (0.78) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL18167491 | 1.00 | MAOB (0.78) | MAOBMAOAKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL17159153 | 0.99 | MAOB (0.77) | MAOBMAOAKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL17158959 | 0.99 | MAOB (0.77) | MAOBMAOAKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL17158961 | 0.99 | MAOB (0.77) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17158831 | 0.93 | MAOB (0.76) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17158759 | 0.91 | MAOB (0.83) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL26428143 | 0.90 | MAOB (0.78) | MAOBMAOAKDM1ARCOR1 | |
| SCHEMBL17159138 | 0.88 | MAOB (1.00) | MAOBMAOAKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| US-10053456-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9920047-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9718814-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9714241-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-25 | — | — | US | disclosed |
| US-20170029417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20170001994-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9487511-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311814-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315735-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20160311808-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-10053456-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 525/4885MAOA 499/4885KDM1A 1/4885 |
| US-10968213-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20170001994-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20170029417-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
| US-20160311814-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | MAOB 495/4885MAOA 493/4885KDM1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.